Research
- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale
November 18, 2020
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the...
Negative Economic Impact of Restricting Drug Rebates in Medicare Part: Matrix Global Advisors
September 02, 2020
“Negative Economic Impact of Restricting Rebates in Medicare Part D,” by Alex Brill of Matrix Global Advisors (MGA), examines recent...
Americans’ Opinions on the Elimination of Rebates in Medicare Part D
August 13, 2020
A majority of seniors say they are satisfied with their prescription drug coverage… Read More...
Insulins: Managing Costs With Increasing Manufacturer Prices
August 11, 2020
Insulin list prices have escalated dramatically during the past 5-10 years. This is due to only three manufacturers controlling the...
Survey Says: Americans 65+ Disapprove of President Trump’s Rebate Rule
August 10, 2020
In a recent survey conducted by Morning Consult on behalf of the Coalition for Medicare Choices, we asked voters 65+...
EMPLOYERS ARE OVERWHELMINGLY SATISFIED WITH THEIR PBMs
July 11, 2020
The vast majority of employers say PBMs are effective at reducing drug costs for their organizations....
Key Findings from Survey of Benefit Managers
June 25, 2020
Our national survey of benefit managers and human resources directors, conducted online June 4-9, 2020, consists of 250 respondents drawn...
Visante: Drug Manufacturer Coupons Raise Costs in Medicare Part D, Hurting Vulnerable Beneficiaries
May 11, 2020
The Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS) currently bans manufacturer coupons...
Visante: Increased Costs Associated With Proposed State Legislation Impacting PBM Tools
April 01, 2020
Visante was commissioned by the Pharmaceutical Care Management Association (PCMA) to estimate the potential cost impact of four types of...
Independent Pharmacies in the U.S. are More on the Rise than on the Decline
March 05, 2020
The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase...
Rebuttal of USC Schaeffer’s “The Association Between Drug Rebates and List Prices”
February 15, 2020
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand...